• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by NanoString Technologies Inc. (Amendment)

    2/13/24 9:50:25 AM ET
    $NSTG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $NSTG alert in real time by email
    SC 13G/A 1 d718661dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    NANOSTRING TECHNOLOGIES, INC.

    (Name of Issuer)

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)

    63009R109

    (CUSIP Number)

    December 31, 2023

    (Date of Event which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ☐

    Rule 13d-1(b)

     

      ☒

    Rule 13d-1(c)

     

      ☐

    Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications:

    Taylor H. Wilson, Esq.

    Haynes and Boone, LLP

    2801 N Harwood St, Suite 2300

    Dallas, Texas 75201

    (214) 651-5000

     

     

     


    SCHEDULE 13G

    CUSIP No. 63009R109

     

     1   

     Names of Reporting Persons

     

     Prosight Management, LP

     2  

     Check the appropriate box if a member of a Group (see instructions)

     

     (a) ☐  (b) ☒

     3  

     Sec Use Only

     

     4  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares

    Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5   

     Sole Voting Power

     

     0

       6  

     Shared Voting Power

     

     0

       7  

     Sole Dispositive Power

     

     0

       8  

     Shared Dispositive Power

     

     0

     9   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     0

    10  

     Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

     

     ☐

    11  

     Percent of class represented by amount in row (9)

     

     0.0%

    12  

     Type of Reporting Person (See Instructions)

     

     IA


    SCHEDULE 13G

    CUSIP No. 63009R109

     

     1   

     Names of Reporting Persons

     

     Prosight Fund, LP

     2  

     Check the appropriate box if a member of a Group (see instructions)

     

     (a) ☐  (b) ☒

     3  

     Sec Use Only

     

     4  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares

    Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5   

     Sole Voting Power

     

     0

       6  

     Shared Voting Power

     

     0

       7  

     Sole Dispositive Power

     

     0

       8  

     Shared Dispositive Power

     

     0

     9   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     0

    10  

     Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

     

     ☐

    11  

     Percent of class represented by amount in row (9)

     

     0.0%

    12  

     Type of Reporting Person (See Instructions)

     

     PN


    SCHEDULE 13G

    CUSIP No. 63009R109

     

     1   

     Names of Reporting Persons

     

     Prosight Plus Fund, LP

     2  

     Check the appropriate box if a member of a Group (see instructions)

     

     (a) ☐  (b) ☒

     3  

     Sec Use Only

     

     4  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares

    Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5   

     Sole Voting Power

     

     0

       6  

     Shared Voting Power

     

     0

       7  

     Sole Dispositive Power

     

     0

       8  

     Shared Dispositive Power

     

     0

     9   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     0

    10  

     Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

     

     ☐

    11  

     Percent of class represented by amount in row (9)

     

     0.0%

    12  

     Type of Reporting Person (See Instructions)

     

     PN


    SCHEDULE 13G

    CUSIP No. 63009R109

     

     1   

     Names of Reporting Persons

     

     Prosight Partners, LLC

     2  

     Check the appropriate box if a member of a Group (see instructions)

     

     (a) ☐  (b) ☒

     3  

     Sec Use Only

     

     4  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares

    Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5   

     Sole Voting Power

     

     0

       6  

     Shared Voting Power

     

     0

       7  

     Sole Dispositive Power

     

     0

       8  

     Shared Dispositive Power

     

     0

     9   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     0

    10  

     Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

     

     ☐

    11  

     Percent of class represented by amount in row (9)

     

     0.0%

    12  

     Type of Reporting Person (See Instructions)

     

     OO


    SCHEDULE 13G

    CUSIP No. 63009R109

     

     1   

     Names of Reporting Persons

     

     W. Lawrence Hawkins

     2  

     Check the appropriate box if a member of a Group (see instructions)

     

     (a) ☐  (b) ☒

     3  

     Sec Use Only

     

     4  

     Citizenship or Place of Organization

     

     United States of America

    Number of

    Shares

    Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5   

     Sole Voting Power

     

     0

       6  

     Shared Voting Power

     

     0

       7  

     Sole Dispositive Power

     

     0

       8  

     Shared Dispositive Power

     

     0

     9   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     0

    10  

     Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

     

     ☐

    11  

     Percent of class represented by amount in row (9)

     

     0.0%

    12  

     Type of Reporting Person (See Instructions)

     

     IN, HC


    Item 1.

     

    (a)

    Name of Issuer:

    NanoString Technologies, Inc. (the “Issuer”)

     

    (b)

    Address of Issuer’s Principal Executive Offices:

    530 Fairview Avenue North

    Seattle, Washington 98109

     

    Item 2.

     

    (a)

    Name of Person Filing:

    This statement is jointly filed by and on behalf of each of Prosight Management, LP, a Delaware limited partnership (“Prosight Management”), Prosight Fund, LP, a Delaware limited partnership (“Prosight Fund”), Prosight Plus Fund, LP, a Delaware limited partnership (“Prosight Plus Fund”), Prosight Partners, LLC, a Delaware limited liability company (“Prosight Partners”), and W. Lawrence Hawkins (collectively referred herein as “Reporting Persons”). Prosight Management is the general partner and investment manager of, and may be deemed to indirectly beneficially own securities owned by, Prosight Fund and Prosight Plus Fund. Prosight Management is a sub-advisor for certain separate managed accounts (collectively, the “Managed Accounts”) and may be deemed to indirectly beneficially own securities owned by the Managed Accounts. Prosight Partners is the general partner of, and may be deemed to beneficially own, securities beneficially owned by Prosight Management. Mr. Hawkins is the sole manager of, and may be deemed to beneficially own securities beneficially owned by, Prosight Partners.

    Each Reporting Person declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, the beneficial owner of any securities covered by this statement.

    Each Reporting Person may be deemed to be a member of a group with respect to the Issuer or securities of the Issuer for the purpose of Section 13(d) or 13(g) of the Act. Each of the Reporting Persons declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purpose of Section 13(d) or 13(g) of the Act or any other purpose, (i) acting (or has agreed or is agreeing to act together with any other person) as a partnership, limited partnership, syndicate, or other group for the purpose of acquiring, holding, or disposing of securities of the Issuer or otherwise with respect to the Issuer or any securities of the Issuer or (ii) a member of any group with respect to the Issuer or any securities of the Issuer.

     

    (b)

    Address of Principal Business Office or, if None, Residence:

    The address of the principal business office of each of the Reporting Persons is c/o Prosight Management, LP, 5956 Sherry Lane, Suite 1365, Dallas, Texas 75225.

     

    (c)

    Citizenship:

    See Item 4 on the cover page(s) hereto.


    (d)

    Title and Class of Securities:

    Common Stock, $0.0001 par value per share (“Common Stock”)

     

    (e)

    CUSIP No.:

    63009R109

     

    Item 3.

    If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)    ☐    Broker or dealer registered under Section 15 of the Act;
    (b)    ☐    Bank as defined in Section 3(a)(6) of the Act;
    (c)    ☐    Insurance company as defined in Section 3(a)(19) of the Act;
    (d)    ☐    Investment company registered under Section 8 of the Investment Company Act of 1940;
    (e)    ☐    An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
    (f)    ☐    An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
    (g)    ☐    A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
    (h)    ☐    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)    ☐    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;
    (j)    ☐    A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);
    (k)    ☐    Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution:    

     

    Item 4.

    Ownership

     

    (a)

    Amount Beneficially Owned as of the time of filing: See Item 9 on the cover pages(s) hereto.

     

    (b)

    Percent of Class as of the time of filing: See Item 11 on the cover page(s) hereto.

     

    (c)

    As of the time of filing, number of shares as to which such person has:

     

      (i)

    Sole power to vote or to direct the vote: See Item 5 on the cover pages hereto.

     

      (ii)

    Shared power to vote or to direct the vote: See Item 6 on the cover pages hereto.

     

      (iii)

    Sole power to dispose or to direct the disposition of: See Item 7 on the cover pages hereto.

     

      (iv)

    Shared power to dispose or to direct the disposition of: See Item 8 on the cover pages hereto.


    Item 5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owners of more than five percent of the class of securities, check the following ☒.

     

    Item 6.

    Ownership of more than Five Percent on Behalf of Another Person.

    Not applicable

     

    Item 7.

    Identification and classification of the subsidiary which acquired the security being reported on by the parent holding company or control person.

    Not applicable

     

    Item 8.

    Identification and classification of members of the group.

    Not applicable

     

    Item 9.

    Notice of Dissolution of Group.

    Not applicable

     

    Item 10.

    Certifications.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the Issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect other than activities solely in connection with a nomination under § 240.14a-11.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: February 13, 2024

     

    PROSIGHT MANAGEMENT, LP

    By:

     

    Prosight Partners, LLC

    Its:

     

    General Partner

    By:

     

    /s/ W. Lawrence Hawkins

    Name:

     

    W. Lawrence Hawkins

    Title:

     

    Sole Manager

    PROSIGHT FUND, LP

    By:

     

    Prosight Management, LP

    Its:

     

    General Partner

    By:

     

    Prosight Partners, LLC

    Its:

     

    General Partner

    By:

     

    /s/ W. Lawrence Hawkins

    Name:

     

    W. Lawrence Hawkins

    Title:

     

    Sole Manager

    PROSIGHT PLUS FUND, LP

    By:

     

    Prosight Management, LP

    Its:

     

    General Partner

    By:

     

    Prosight Partners, LLC

    Its:

     

    General Partner

    By:

     

    /s/ W. Lawrence Hawkins

    Name:

     

    W. Lawrence Hawkins

    Title:

     

    Sole Manager

    PROSIGHT PARTNERS, LLC

    By:

     

    /s/ W. Lawrence Hawkins

    Name:

     

    W. Lawrence Hawkins

    Title:

     

    Sole Manager

    W. LAWRENCE HAWKINS

    /s/ W. Lawrence Hawkins


    EXHIBIT INDEX

     

    Exhibit   

    Description of Exhibit

    99.1    Joint Filing Agreement (incorporated herein by reference to Exhibit 99.1 to the Schedule 13G filed on September 1, 2023, by the Reporting Persons with the SEC).
    Get the next $NSTG alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $NSTG

    DatePrice TargetRatingAnalyst
    11/27/2023Overweight → Neutral
    JP Morgan
    11/21/2023Outperform → Neutral
    Robert W. Baird
    7/5/2023$18.00Overweight
    JP Morgan
    2/2/2023$15.00Buy
    UBS
    3/24/2022$50.00Buy
    Canaccord Genuity
    3/2/2022$85.00 → $70.00Overweight
    JP Morgan
    More analyst ratings

    $NSTG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Beechem Joseph M was granted 564 shares, increasing direct ownership by 0.60% to 95,017 units

      4 - NanoString Technologies Inc (0001401708) (Issuer)

      9/5/23 4:38:19 PM ET
      $NSTG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4: Gray R Bradley was granted 287 shares, increasing direct ownership by 0.08% to 338,682 units

      4 - NanoString Technologies Inc (0001401708) (Issuer)

      9/5/23 4:36:22 PM ET
      $NSTG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Garland Jonathan Todd

      4 - NanoString Technologies Inc (0001401708) (Issuer)

      8/28/23 4:26:32 PM ET
      $NSTG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NSTG
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NanoString Announces Completion of Financing to Support Restructuring Process

      $47.5 Million in New Financing Secured from Existing Noteholders, Upsized from Initial $40 million Commitment Supports Mission to Continue Serving Life Sciences Researchers Worldwide NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced the Company has entered into a credit agreement with its existing lenders comprised of (a) $12,500,000 in new money term loans which have already been approved for funding pursuant to the February 5 interim order of the U.S. Bankruptcy court approving the credit facility, and (b) an additional $35,000,000 in new money term loans to be funded upon entry of the final

      2/9/24 6:30:00 AM ET
      $NSTG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • NanoString Takes Steps to Restructure Its Business and Protect Its Mission to Map the Universe of Biology

      Initiates Voluntary Chapter 11 Restructuring Proceedings with Additional $40 Million in Financing Secured from Existing Noteholders to Facilitate Process Continuing to Serve Life Sciences Researchers Worldwide NanoString Technologies, Inc. (NASDAQ:NSTG) ("NanoString" or "the Company"), a leading provider of life science tools for discovery and translational research, today announced that steps are being taken to protect its business, customers, employees and its mission to "Map the Universe of Biology." With support from key creditors, NanoString and certain of its subsidiaries have voluntarily initiated a chapter 11 restructuring proceeding in the United States Bankruptcy Court for the

      2/4/24 7:45:00 PM ET
      $NSTG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • NanoString Launches the CosMx 6,000 plex RNA Assay and Showcases Whole Transcriptome Imaging Capability

      Three customers will present inaugural studies powered by the novel CosMx Whole Transcriptome Panel during annual AGBT meeting NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced the commercial availability of the CosMx™ Human 6K Discovery Panel, the industry's first single-cell spatial panel enabling research scientists to measure over 6,000 RNA targets, representing nearly every human biological pathway. Building on this breakthrough product developed for the CosMx Spatial Molecular Imager (SMI), NanoString and independent researchers will also highlight recently achieved whole transcriptome imag

      2/1/24 6:00:00 AM ET
      $NSTG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NSTG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by NanoString Technologies Inc. (Amendment)

      SC 13G/A - NanoString Technologies Inc (0001401708) (Subject)

      2/14/24 5:16:00 PM ET
      $NSTG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by NanoString Technologies Inc. (Amendment)

      SC 13G/A - NanoString Technologies Inc (0001401708) (Subject)

      2/14/24 5:01:20 PM ET
      $NSTG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by NanoString Technologies Inc.

      SC 13G - NanoString Technologies Inc (0001401708) (Subject)

      2/14/24 4:49:47 PM ET
      $NSTG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NSTG
    Financials

    Live finance-specific insights

    See more
    • NanoString Technologies Releases Operating Results for Third Quarter of 2023

      Completed Exchange Transaction with Convertible Note Holders Representing 94% of Outstanding Principal – Record Q3 Revenue of $48.1 Million, 63% Year on Year Growth and Above Upper End of Q3 Guidance Range – NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today reported financial results for the third quarter ended September 30, 2023. The Company also announced it had reached agreement with holders to exchange approximately $216 million, or 94%, principal amount of its Convertible Notes for new Senior Secured Notes due September 1, 2026 and common stock warrants. "The last few months have been extraordinar

      11/6/23 4:00:00 PM ET
      $NSTG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • NanoString Provides Preliminary Financial and Operational Highlights for Third Quarter of 2023

      - Record Q3 Revenue of Over $48 Million, 63% Year on Year Growth, Above Upper End of Q3 Guidance Range - - Implementing Reorganization of R&D and Manufacturing Operations to Improve Path to Profitability - NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today reported preliminary financial and operational highlights for the third quarter ended September 30, 2023, as well as a reorganization designed to accelerate the Company's path to profitability. "Our teams delivered strong revenue results for the third quarter, with preliminary results exceeding consensus estimates and the high end of our guidance rang

      10/10/23 6:00:00 AM ET
      $NSTG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • NanoString Technologies Releases Operating Results for Second Quarter of 2023

      – Record Q2 Revenue of $44.2 Million, 37% Year on Year Growth and Above Upper End of Q2 Guidance Range – - Retained More than $35 Million in CosMx Instrument Order Backlog at the End of Q2 - NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today reported financial results for the second quarter ended June 30, 2023. "Strong growth in our spatial biology business and continued durability in our nCounter business helped us generate record revenue during the second quarter," said Brad Gray, President and CEO of NanoString. "We expect to continue to benefit from substantial CosMx instrument order backlog through

      8/3/23 4:00:00 PM ET
      $NSTG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NSTG
    SEC Filings

    See more
    • NanoString Technologies Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Financial Statements and Exhibits

      8-K - NanoString Technologies Inc (0001401708) (Filer)

      2/13/24 5:24:14 PM ET
      $NSTG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • NanoString Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

      8-K - NanoString Technologies Inc (0001401708) (Filer)

      2/8/24 10:45:26 AM ET
      $NSTG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • NanoString Technologies Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Events That Accelerate or Increase a Direct Financial Obligation, Other Events, Financial Statements and Exhibits

      8-K - NanoString Technologies Inc (0001401708) (Filer)

      2/5/24 6:01:37 AM ET
      $NSTG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NSTG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • NanoString Technologies downgraded by JP Morgan

      JP Morgan downgraded NanoString Technologies from Overweight to Neutral

      11/27/23 7:30:05 AM ET
      $NSTG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • NanoString Technologies downgraded by Robert W. Baird

      Robert W. Baird downgraded NanoString Technologies from Outperform to Neutral

      11/21/23 7:36:01 AM ET
      $NSTG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • JP Morgan resumed coverage on NanoString Technologies with a new price target

      JP Morgan resumed coverage of NanoString Technologies with a rating of Overweight and set a new price target of $18.00

      7/5/23 7:22:55 AM ET
      $NSTG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NSTG
    Leadership Updates

    Live Leadership Updates

    See more
    • NanoString Appoints Todd Garland as Chief Commercial Officer

      NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for discovery and translational research, today announced that Todd Garland has been appointed Chief Commercial Officer, effective August 28, 2023. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230826560279/en/NanoString Appoints Todd Garland as Chief Commercial Officer (Photo: Business Wire) Mr. Garland is a senior executive with more than 25 years of experience in healthcare and life sciences technologies that serve customers in the discovery, translational and clinical markets. Most recently Mr. Garland served as Chief Commercial Officer at Cytek B

      8/28/23 5:53:00 AM ET
      $NSTG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • DermTech Appoints Two New Board Members

      DermTech, Inc. (NASDAQ:DMTK) ("DermTech" or the "Company"), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced the appointment of Kirk D. Malloy, Ph.D. and Mark C. Capone, M.S. to the Company's board of directors, effective July 18,2022. These appointments expand DermTech's board of directors to eight members. "We are excited to welcome Kirk and Mark as new independent directors," commented Matt Posard, DermTech's chairman. "They are both accomplished life science executives, with an established track record in building companies, business development, capital formation and strategic partnerships. Their perspectives in guiding high-growth co

      7/18/22 4:05:00 PM ET
      $DMTK
      $NSTG
      Medical Specialities
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • NanoString Appoints Dr. Teresa Foy to Board of Directors

      Dr. Rob Hershberg steps down from Board after seven years of service NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced the appointment of Dr. Teresa (Teri) Foy to the Board of Directors, effective April 18, 2022. "I am honored to welcome Dr. Foy to the team. Teri is a leader in immuno-oncology and cellular therapy, with decades of experience in pharmaceutical research," said president and chief executive officer Brad Gray. "Immunology and oncology are two of the most important applications for spatial biology, and Teri brings a wealth of knowledge in the ways that life science tools are utilized

      4/18/22 4:00:00 PM ET
      $NSTG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care